Muscle-Invasive Bladder Cancer at the Cisplatin Eligibility Line
A creatinine clearance sitting right at the edge of the cisplatin-eligibility threshold turns a normally straightforward decision — neoadjuvant chemotherapy before cystectomy — into a genuine judgment call about which compromise costs him the least.
F.O., a 69-year-old man, has lived in the same converted farmhouse for forty years, most of it spent maintaining the surrounding acreage himself — a routine his family says has kept him stronger than most men a decade younger, though longstanding hypertension has left him with chronically reduced kidney function he'd never had reason to think much about until now. Cystoscopy for gross hematuria found a bladder mass, and transurethral resection confirmed muscle-invasive urothelial carcinoma — disease at the stage where neoadjuvant cisplatin-based chemotherapy before radical cystectomy has a real, guideline-supported survival benefit over surgery alone. His calculated creatinine clearance came back at 52mL/min — below the 60mL/min floor the Galsky consensus criteria use to define cisplatin eligibility, but inside the 50-to-60 band many centers now treat with a modified schedule rather than excluding outright. Read against his own history, that number is not a new insult to be corrected before treatment: it is the settled endpoint of decades of hypertensive nephropathy, which means waiting will not improve it.
Three real paths exist at this exact renal-function boundary. Split-dose cisplatin, giving the dose divided across two days of each cycle rather than as a single infusion, has been studied specifically in patients with borderline renal function like his — Hussain and colleagues and several subsequent series report response rates approaching those of standard scheduling with less acute nephrotoxicity — though none of that evidence comes from a randomized comparison against the standard schedule. Carboplatin, substituted for cisplatin entirely, avoids the renal threshold question outright but has never matched cisplatin's efficacy in curative-intent bladder cancer regimens; no carboplatin-based neoadjuvant schedule has demonstrated the survival benefit SWOG 8710 showed for cisplatin, which makes the swap a real downgrade rather than a lateral substitution. Proceeding directly to cystectomy without any neoadjuvant chemotherapy avoids the renal question entirely but forgoes the survival benefit SWOG 8710 (Grossman et al.) established for neoadjuvant cisplatin-based chemotherapy over cystectomy alone — a benefit that exists specifically because systemic disease is often already present at surgery and undetectable on imaging. His baseline audiometry and neuropathy screen, drawn specifically because any cisplatin-containing plan requires them, both came back normal — one fewer variable narrowing the choice, since a pre-existing hearing deficit or peripheral neuropathy would have argued against cisplatin in either dosing schedule regardless of his renal function.
Choosing a neoadjuvant regimen at the eligibility line
I'd try split-dose cisplatin. Hussain's work and the series that followed it studied exactly this population — creatinine clearance in the fifties — and report response rates close to standard scheduling with less acute renal injury. What we're protecting here is SWOG 8710's survival benefit, which is cisplatin's, not platinum's generally.
His renal impairment isn't a transient finding we're waiting to resolve — it's chronic, structural damage from decades of hypertension. And the split-dose evidence you're leaning on is single-arm; nobody has randomized split against standard scheduling at a clearance of 52, so what we actually have is a series of patients who did acceptably, not a demonstration that the efficacy survives the modification. I'd rather use carboplatin and accept a known efficacy tradeoff than accept an unmeasured one alongside real renal risk.
"Gentler" isn't "safe" — it's still cisplatin, still nephrotoxic, in a kidney with no functional reserve to spare.
Both of you are arguing from what the evidence can't settle, and I'd rather structure around that than pick a side of it. His audiometry and neuropathy screen are clean and his clearance is stable rather than falling, so the monitored attempt has a real floor under it. I'd try split-dose cisplatin with clearance checked before every dose and a pre-agreed threshold for switching to carboplatin mid-course — which converts the unmeasured risk you're both worried about into something we observe rather than predict.
Agreed: split-dose cisplatin with gemcitabine started, creatinine clearance rechecked before every weekly dose, and a specific threshold decline agreed in advance for switching to carboplatin mid-course.
Not agreed, and named as a real, unresolved disagreement about risk tolerance:
Believe the monitored attempt at cisplatin is worth the risk given his excellent overall function and the regimen's demonstrated survival benefit.
Would have started with carboplatin from the outset, viewing any cisplatin exposure in chronically impaired kidneys as an avoidable risk regardless of monitoring.